Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 196998
                    [Title] => New anti-cholesterol drug in the market
                    [Summary] => Management of coronary heart disease (CHD), a major cause of death in the Western world and commonly associated with atherosclerosis, recently got a new boost with the approval by Canadian authorities of Rosuvastatin for the management of primary hypercholesterolaemia, mixed dyslipidaemia, and familial hypercholesterolaemia, conditions better known as "high cholesterol."


Canadian medical experts agree that low density lipoprotein (LDL-C), commonly known as the "bad" cholesterol, is the most significant contributory risk factor for atherosclerosis.


                    [DatePublished] => 2003-02-27 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

BETALOC AND IMDUR

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 196998
                    [Title] => New anti-cholesterol drug in the market
                    [Summary] => Management of coronary heart disease (CHD), a major cause of death in the Western world and commonly associated with atherosclerosis, recently got a new boost with the approval by Canadian authorities of Rosuvastatin for the management of primary hypercholesterolaemia, mixed dyslipidaemia, and familial hypercholesterolaemia, conditions better known as "high cholesterol."


Canadian medical experts agree that low density lipoprotein (LDL-C), commonly known as the "bad" cholesterol, is the most significant contributory risk factor for atherosclerosis.


                    [DatePublished] => 2003-02-27 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

New anti-cholesterol drug in the market

February 27, 2003 - 12:00am

Management of coronary heart disease (CHD), a major cause of death in the Western world and commonly associated with atherosclerosis, recently got a new boost with the approval by Canadian authorities of Rosuvastatin...

Science and Environment